Lv21
110 积分 2023-01-29 加入
Defining an evidence-based strategy for streamlining cancer multidisciplinary team meetings
2小时前
求助中
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study
3小时前
已完结
The landscape of cancer research and cancer care in China
4天前
已完结
Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma
24天前
已完结
2016
29天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
1个月前
已完结
Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema
1个月前
已完结
Fcγ receptors and immunomodulatory antibodies in cancer
1个月前
已完结
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
1个月前
已完结
VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
1个月前
已完结
皖公网安备34019202002308
